Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Clinical and Research Excellence Index

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Support for fast pharmaceutical regulatory approval

Our intelligence on approved and pipeline drugs, plus regulatory information on devices/diagnostics help you plan your route to commercial success.

Your window on the pipeline

To achieve commercial success, you need to connect successful approved drugs and mid-to-late stage pipeline drugs to the underlying trial information. You’ll also want to focus in on the best trial designs and comparator arms that have met with success across target markets.

What we offer

Our solutions give you the tools and intelligence to quickly build up a landscape of approved and pipeline drugs for a disease of interest. We cover where drugs have been approved or are in development, and timeline projections for clinical trials and time to regulatory approvals.
You’ll also be able to find comprehensive, accurate regulatory information on devices/diagnostics, particularly for FDA and CE Mark approvals.
Plus, you can save time filtering information by mechanism of action or drug class.

How it helps

We’ll help you:

Stay up to date with new regulatory trends/changes in pharma and medtech
Anticipate label claims of your competitors and ensure your product has a strong and promising future in the market
Learn from the pitfalls of terminated trials for similar drugs
Understand successful (and unsuccessful) strategies to achieve priority regulatory designations, that you can incorporate into your own development plans
Tap into the industry’s top analysts to help with your research needs

Relevant products

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

View all content

Pink Sheet

COVID-19 Staff Shakeup: Woodcock Moves to Commissioner's Office As Marks Drops Out Of 'Warp'

CBER Director Marks will no longer have to recuse himself from COVID-19 product reviews, a move seen as resoundingly positive by former senior FDA leaders. CDER Director Woodcock will now be free to focus solely on COVID-19 and bring her unique depth of agency experience to the Trump Administration's effort to speed development of vaccines, therapeutics and diagnostics for coronavirus.

Topic Coronavirus

View article
Pink Sheet

What The Pandemic Can Teach Us About Running Clinical Trialssample content insights page

Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.

Topic Coronavirus

View article
HBW Insight

CBD News Round-Up: Australia Proposes OTC Pathway, First EU Novel Food Validation, COVID Boost For UK Firm

Australia looks at switching CBD as an OTC medicine, CBDepot becomes the first European firm with an EU Novel Food validation and the UK's Vitality CBD gets a boost from the global, coronavirus-driven wellness trend.

Topic Dietary Supplements Coronavirus

View article
HBW Insight

IFRA Chair Looks Forward To Post-COVID-19 ‘Revival Of Reason’

IFRA’s new chairman Hans Holger Gliewe says one possible positive outcome of the COVID-19 pandemic could be that consumers go on putting a premium on scientific expertise after months of reliance on health experts’ advice.

Topic Coronavirus Cosmetics

View article
Generics Bulletin

Celltrion Sets Out Plans To Trial Coronavirus Treatments

In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

Topic Coronavirus

View article
HBW Insight

Bayers Supplement Sales Leap By A Third On COVID Boost

Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic.

Topic Coronavirus

View article
Generics Bulletin

Biosimilars Conference Coverage

Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

Topic Biosimilars

Single report
Pharmaprojects, Biomedtracker

The Race to Find a COVID-19 Treatment - Infographic

Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.

Topic Coronavirus FDA Drug Review

View infographic
Pink Sheet

Pink Sheet European Regional Coverage

Gain insights into new European regulatory events and developments with expert coverage from Pink Sheet. You’ll discover vital news and insight regarding Brexit, approvals for novel therapies, drug safety related updates, and more from our worldwide and on-the-ground team of expert journalists and analysts.

Single report
Pink Sheet

European Performance Tracker

Explore European coverage with informative articles covering recent regulatory and policy developments in the region. We now invite you to go even deeper, with regulatory market intelligence from Pink Sheet’s European Performance Tracker.

Single report
Generics Bulletin

Celltrion Will Trial COVID-19 Antiviral From July

Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

Topic Coronavirus Vaccines

View article
Generics Bulletin

Australian Bodies Set Out Joint Position On Coronavirus

Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

View article
Biomedtracker

A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.

View white paper
HBW Insight

‘Insufficient Evidence’ Ibuprofen Worsens COVID-19, Says UK Regulator

Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms.

Topic Coronavirus

View article
Pink Sheet

EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.

Topic Coronavirus

View article